About Monograph
Monograph is a venture capital firm founded in 2021. It is primarily based out of London, United Kingdom. As of Jun 2026, Monograph is an active investor, having invested in 16 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of RQ Bio Overall, Monograph portfolio has seen 1 IPO and 3 acquisitions including key companies like UroGen Pharma, Ouro Medicines and MiroBio. A lot of funds co-invest with Monograph, with names like New Enterprise Associates sharing a substantial percentage of its portfolio. Monograph has team of 10 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Acquisitions
Monograph's List of Top Investments
Monograph has a portfolio of 16 companies. Their most notable investments are in Nocion Therapeutics and Nocion Therapeutics.Their portfolio spans across United Kingdom, United States, Canada and 3 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 2 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by Monograph:
1. AviadoBio
Developer of gene therapies for neurodegenerative disorders. The company is developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company's product candidate include AVB-PGRN an adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the Progranulin (GRN) gene.
Key facts about AviadoBio
- Founded Year: 2019
- Location: London (United Kingdom)
- Annual Revenue: £10M - £50M as on Dec 31, 2025
- Stage: Series A
- Total Funding till date: $80M
- Employee Count: 72 as on Sep 30, 2026
- Investors: Advent Life Sciences, Life Sciences Partners and 9 Others
- Latest Funding Round: Series A, Dec 02, 2021, $*****
- Highlight: Editors' Pick
Developer of therapeutics to treat urothelial and specialty cancers. The company uses proprietary technology RTGel to deliver targeted therapies which include "Jelmyto" for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer.
Key facts about UroGen Pharma
- Founded Year: 2004
- Location: Ra anana (Israel)
- Stage: Public
- Total Funding till date: $7M
- Employee Count: 343 as on Sep 30, 2026
- Investors: RTW Investments, RA Capital Management and 12 Others
- Latest Funding Round: Post IPO, Jul 27, 2023, $*****
- Highlight: Public
3. ODAIA
Provider of AI-powered intelligence platform for pharmaceutical commercial and sales teams. The platform delivers relevant targets, prioritized call lists, and personalized insights. It helps sales representatives engage with healthcare professionals. The platform identifies trends and patterns in engagements, empowering managers with actionable insights. It offers dynamic segmentation and targeting to optimize commercial resources.
Key facts about ODAIA
- Founded Year: 2018
- Location: Toronto (Canada)
- Stage: Series B
- Total Funding till date: $44.5M
- Employee Count: 105 as on Sep 30, 2026
- Investors: Inovia Capital, Threshold and 19 Others
- Latest Funding Round: Series B, May 01, 2023, $*****
- Highlight: Editors' Pick
_1556602763814.png?format=webp&height=120&width=120){kind=logo}
4. RegAsk
Provider of artificial intelligence software for global regulatory compliance management. The platform enables organizations to monitor regulatory changes, analyze compliance data, and streamline workflows through automated systems. It integrates real-time signals, risk assessment tools, and task management features to assist teams in navigating international requirements. The solution utilizes machine learning algorithms and connects users with a community of subject matter experts to facilitate research, impact assessments, and documentation. Features include dashboard reporting, API integrations, and secure data storage to support product lifecycle and regulatory readiness.
Key facts about RegAsk
- Founded Year: 2018
- Location: Singapore (Singapore)
- Annual Revenue: $1M - $10M as on Dec 31, 2023
- Stage: Series A
- Total Funding till date: $10M
- Employee Count: 85 as on Sep 30, 2026
- Investors: Monograph, Roland Investments and 12 Others
- Latest Funding Round: Series A, Dec 15, 2022, $*****
- Highlight: Editors' Pick
Developer of antibody-based drugs to treat multiple diseases. The company leverages a proprietary KnotBody technology that combines the power of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques to address autoimmunity, chronic pain, and cardiovascular diseases.
Key facts about Maxion Therapeutics
- Founded Year: 2020
- Location: Cambridge (United Kingdom)
- Stage: Series A
- Total Funding till date: $88M
- Employee Count: 57 as on Sep 30, 2026
- Investors: Lilly, Solasta Ventures and 10 Others
- Latest Funding Round: Series A, Mar 17, 2025, $*****
- Highlight: Editors' Pick
Monograph's Year-on-Year Investment Trends
Monograph has invested in 16 companies over the last 5 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 6 investments, while as of Jun 2026, it has made 2 investments in this year. Its most recent first time investment was in RQ Bio and most recent follow-on round was in Ollin.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 4 | 2 | 6 |
2024 | 2 | 0 | 2 |
2023 | 4 | 0 | 4 |
2022 | 3 | 0 | 3 |
2021 | 1 | 0 | 1 |
Monograph's Investments by Stage
Monograph has made 8 investments in Series A stage with an average round size of $72.6M, 5 investments in Series B stage with an average round size of $84M, 1 investment in Post IPO stage with an average round size of $120M and 1 investment in Series C stage with an average round size of $101M.Stage of entry | No. of Investments |
|---|---|
Series A | 8 |
Series B | 5 |
Post IPO | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
Monograph's Investments by Sector
Monograph has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Sustainability Tech. Notably, it has invested in 15 Tech companies, 14 Enterprise (B2B) companies, 2 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
Enterprise Applications | 2 |
HealthTech | 1 |
High Tech | 1 |
Sustainability Tech | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Monograph's Investments by Geography
Monograph has made most investments in United States (6), followed by United Kingdom where it has made 5 investments.Country | No. of Investments |
|---|---|
United States | 6 |
United Kingdom | 5 |
Canada | 1 |
China | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Monograph's recent investments
Monograph has made 2 investments in 2026 so far - RQ Bio and Ollin.Here are the most recent investments by Monograph:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 24, 2026 | United Kingdom | Series A | 6561 | [+6] | |
May 14, 2026 | United States | Series B | 3873 | [+8] | |
Dec 15, 2025 | United States | Series B | 8124 | [+8] | |
Dec 11, 2025 | United States | Series A | 9429 | [+1] | |
Oct 22, 2025 | United Kingdom | Series A | 6122 | [+2] |
IPOs and Publicly Listed companies in Monograph's Portfolio
1 of Monograph's portfolio company became public - UroGen Pharma. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2017 at marketcap of $156MHere are Monograph's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 04, 2017 | Jul 27, 2023 | Post IPO | 5190 |
Acquired companies in Monograph's Portfolio
3 companies from Monograph's portfolio have been acquired. The most recent acquisition was Ouro Medicines in Mar 2026 by Gilead for $*****.Here are Monograph's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 23, 2026 | Jan 10, 2025 | Series A | 4659 | |
May 22, 2024 | Nov 01, 2022 | Series B | 5624 | |
Aug 04, 2022 | Jun 21, 2022 | Series B | 1668 |
Team profile of Monograph
Monograph has a team of 10 members including 3 Partners and 3 Principals located in United States and United Kingdom. Monograph's team does not sit on the board of any company as of now.Here is a list of all team members in Monograph:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | London | - | ||
Partner | San Francisco | - | - | |
Partner | Washington | - | ||
Principal | San Francisco | - | ||
Principal | Washington | - | ||
Principal | London | - |
Co-investors of Monograph
Over the past 5 years, 110 investors have co-invested in Monograph's portfolio companies. This includes funds and angels.
- Invested before Monograph: Samsara BioCapital, RTW Investments and 36 others have invested in rounds before Monograph. There are 2 companies where Samsara BioCapital has invested before Monograph and 1 company where RTW Investments has invested before Monograph.
- Top Co-investors of Monograph: 51 investors entered a company along with Monograph. These include investors like New Enterprise Associates (2 companies).
- Invested after Monograph: A total of 21 investors have invested in Monograph's portfolio after their investments. Top Investors include Gov (1 company), General Catalyst (1 company) and British Patient Capital (1 company).
Recent News related to Monograph
•
EQT Life Sciences Participates in RQ Bio's USD 115 Million Series A FinancingPR Newswire•Jun 24, 2026•Frazier Life Sciences, EQT, RQ Bio, Forbion and 6 others
•
Weight loss biotech Prolynx gets $70M, hires Amgen's obesity commercial leader as CEOEndpoints•Dec 11, 2025•Amgen, ProLynx, 5AM Ventures, Orbimed and 2 others
•
Elevara Medicines Secures $70M to Test Breast Cancer Approach in Rheumatoid ArthritisEndpoints•Oct 22, 2025•Elevara Medicines, Hastingstribune, Monograph, Sofinnova Partners and 4 others
•
Maxion Therapeutics raises $72m in oversubscribed Series A financing to advance KnotBody pipeline and platformPharma Business International•Mar 18, 2025•Maxion Therapeutics, General Catalyst, Lilly, Solasta Ventures and 5 others
•
Maxion Therapeutics Raises $72M in Series A FundingFinSMEs•Mar 17, 2025•Maxion Therapeutics, General Catalyst, British Patient Capital, Solasta Ventures and 4 others
•
•
Cambridge-based Maxion Therapeutics Secures €68.9 Million in Series A Round FundingStartup Rise EU•Mar 17, 2025•Maxion Therapeutics, BGF, Monograph, LifeArc Ventures and 4 others
•
Maxion Therapeutics bags £58m for its biologic drug modality in the largest European private biotech funding round since 2024Tech Funding News•Mar 17, 2025•Maxion Therapeutics, General Catalyst, British Patient Capital, Solasta Ventures and 5 others
•
Maxion Therapeutics secures $72M in oversubscribed Series A funding to develop its Knotbody® technology.GlobeNewswire•Mar 17, 2025•Maxion Therapeutics, General Catalyst, British Patient Capital, Solasta Ventures and 5 others
•
Orbis Medicines bags €90 million Series A to develop oral competitors of biologicsOutsourcing-Pharma•Jan 06, 2025•Orbis Medicines, New Enterprise Associates, Lilly, Cormorant Capital and 17 others
